HLA class II haplotypes predict favorable outcomes for patients with metastatic RCC.
Ellerhorst
J A
JA
The University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030-4095, USA. jaellerh@mail.mdanderson.com
Hildebrand
W H
WH
Cavett
J W
JW
Fernandez-Vina
M A
MA
Hodges
S
S
Poindexter
N
N
Fischer
H
H
Grimm
E A
EA
D000483:Alleles; D000951:Antigens, Neoplasm / Q000276:immunology; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000235:genetics* / Q000276:immunology / Q000401:mortality; D016207:Cytokines / Q000627:therapeutic use; D018572:Disease-Free Survival; D005787:Gene Frequency / Q000235:genetics; D006580:Genetic Carrier Screening; D005838:Genotype; D006239:Haplotypes; D000949:Histocompatibility Antigens Class II / Q000235:genetics*; D006650:Histocompatibility Testing; D006720:Homozygote; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000276:immunology / Q000401:mortality*; D009362:Neoplasm Metastasis / Q000188:drug therapy / Q000276:immunology; D011379:Prognosis; D016896:Treatment Outcome
D000951:Antigens, Neoplasm; D016207:Cytokines; D000949:Histocompatibility Antigens Class II